Children With Metabolically Healthy Obesity: A Review

Rade Vukovic1,2, Tiago Jeronimo Dos Santos3, Marina Ybarra4,5

  • 1Department of Pediatric Endocrinology, Mother and Child Healthcare Institute of Serbia "Dr Vukan Cupic", Belgrade, Serbia.

Insights

Children with metabolically healthy obesity (MHO) show fewer cardiometabolic risks. Understanding MHO

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Health
  • Obesity Research

Background:

  • Metabolically healthy obesity (MHO) in children is a distinct subgroup with reduced cardiometabolic risk factors.
  • A consensus definition for pediatric MHO was established in 2018, building on earlier descriptions from the 1980s.
  • MHO is often defined by the absence of metabolic syndrome components or insulin resistance.

Purpose of the Study:

  • To provide a concise review of the current knowledge on the MHO phenomenon in youth.
  • To summarize key findings regarding prevalence, predictors, and underlying mechanisms of pediatric MHO.

Main Methods:

  • Literature review summarizing existing research on pediatric metabolically healthy obesity.
  • Analysis of studies reporting prevalence, associated factors, and potential protective mechanisms.
  • Synthesis of findings related to cardiometabolic risk, clinical outcomes, and management strategies.

Main Results:

  • Prevalence of pediatric MHO varies widely (3-87%) based on definition, ethnicity, and pubertal status.
  • Key predictors include younger age, lower BMI, waist circumference, and body fat.
  • Emerging evidence points to adipokines, adipose tissue inflammation, and visceral fat reduction as crucial factors.

Conclusions:

  • While MHO offers some protection against cardiometabolic risks, potential issues like hepatic steatosis exist.
  • Screening and lifestyle modifications (sleep, diet, activity) are crucial for at-risk children.
  • Further research is needed to understand protective mechanisms and develop targeted treatments for pediatric obesity.

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
133
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
152
Regulation of Metabolism01:19

Regulation of Metabolism

Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
11.3K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
193
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
654